Are there antibody-drug conjugates approved for Carcinoid Tumors
Antibody-Drug Conjugates for Carcinoid Tumors
Based on current medical guidelines, there are no FDA-approved antibody-drug conjugates (ADCs) specifically for carcinoid tumors at this time.
What This Means
Carcinoid tumors are neuroendocrine tumors (NETs) that arise from hormone-producing cells. According to the NCCN Guidelines for Neuroendocrine and Adrenal Tumors (Version 3.2025), the standard treatment approaches for advanced carcinoid tumors typically include:
- Somatostatin analogs (octreotide LAR, lanreotide) - to control hormone-related symptoms
- Peptide receptor radionuclide therapy (PRRT) with lutetium Lu 177 dotatate - a targeted radioactive treatment
- Chemotherapy (cisplatin/etoposide, carboplatin/etoposide, temozolomide)
- Targeted therapies like everolimus or cabozantinib
- Immunotherapy (pembrolizumab) for specific biomarker-positive tumors
Why ADCs Might Be Relevant
While ADCs aren't currently approved for carcinoid tumors specifically, they ARE approved for other cancer types. For example, trastuzumab deruxtecan (an HER2-targeting ADC) is used in various cancers. If your carcinoid tumor has specific biomarkers (like HER2 expression), your oncologist might discuss whether an ADC could be considered off-label or through a clinical trial.
Questions to Ask Your Oncologist
- Has my tumor been tested for HER2 expression or other biomarkers that might respond to antibody-drug conjugates?
- Are there any clinical trials available for ADCs in carcinoid tumors?
- What are the standard treatment options recommended for my specific type and stage of carcinoid tumor?
- Would off-label use of an ADC be appropriate for my case?
According to the NCCN Guidelines, treatment decisions for carcinoid tumors should be individualized based on tumor location, grade, biomarkers, and disease burden.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated May 23, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for Carcinoid_tumors patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Carcinoid_tumors
- What is oligometastatic Carcinoid Tumors and can it still be cured
- Should I do chemotherapy before or after surgery for Carcinoid Tumors
- What is ctDNA testing and should Carcinoid Tumors patients get it
- Should I get a comprehensive genomic panel for Carcinoid Tumors
- How does Carcinoid Tumors treatment affect fertility
- Can I work during Carcinoid Tumors treatment
- What are the signs of Carcinoid Tumors recurrence and how is it monitored
- What is maintenance therapy for Carcinoid Tumors and when is it recommended